comparemela.com

Latest Breaking News On - கிறிஸ் கிப்சன் - Page 4 : comparemela.com

Utah AI/biotech innovator Recursion Pharmaceuticals doubling SLC HQ

Deseret News Share this story Lawrie Allred, HTS engineer, hands a cell plate to a co-worker while seeding cells at Recursion Pharmaceuticals at The Gateway in Salt Lake City on Oct. 30, 2018. This week, the company announced it will double the footprint of its flagship research and office facility, signing a lease on an additional 100,000 square feet of space at The Gateway. Kristin Murphy, Deseret News Utah biotech startup Recursion Pharmaceuticals is upending the realm of clinical-stage drug research, melding robot-driven automation with digital artificial intelligence on a mission to revolutionize how new medications are developed to battle some of the rarest and most challenging of human medical conditions.

Utah AI/biotech innovator Recursion Pharmaceuticals is growing (and earning) fast Here s why

SALT LAKE CITY Utah biotech startup Recursion Pharmaceuticals is upending the realm of clinical-stage drug research, melding robot-driven automation with digital artificial intelligence on a mission to revolutionize how new medications are developed to battle some of the rarest and most challenging of human medical conditions. And the company has been on an absolute tear in the last year, raising over $500 million via a public stock offering in April, expanding its footprint with a new research facility in Toronto and growing its staff by over 60%. It also has four medications currently in clinical trials. Recursion was founded in 2013 and outgrew two facilities at University of Utah s Research Park before taking over a 100,000-plus-square-foot space in downtown s Gateway center, the former home of Dick s Sporting Goods. This week, the company announced it will double the footprint of its flagship research and office facility, signing a lease on an additional 100,000 square feet

Follow the Money: AI-Powered Drug Discovery, Remote Access Labs

July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.